

Requester: Pharma

Date: September 2009

Purpose: Use within a PBAC submission

The following report is based on the Australian HIV Observational Database (AHOD) up to March 31, 2009. By this time a total of 2921 patients were enrolled to AHOD.

Table 1: Proportion of treatment naïve patients who commenced treatment after 1st January 2005, on the following regimens

Regimen	(N=285)	%
Efavirenz + 2NRTI	117	41
Nevirapine + 2NRTI	51	18
Atazanavir + 2NRTI	22	8
Kaletra + 2NRTI	23	8
Other PI + 2NRTI	26	9
Other regimens ¹	46	16

1. Includes mono/dual therapy and other HAART regimens

Table 2: Proportion of treatment naïve patients who commenced treatment after 1st January 2005, On the following regimens by initiation year

Regimen	2005		2006		2007		2008-2009 ¹	
	(N=55)	(N=55)	(N=71)	(N=71)	(N=71)	(N=71)	(N=88)	(N=88)
Regimen	N	%	N	%	N	%	N	%
Efavirenz + 2NRTI	19	35	28	39	38	54	32	36
Nevirapine + 2NRTI	6	11	8	11	13	18	24	27
Atazanavir + 2NRTI	0	0	8	11	7	10	7	8
Kaletra + 2NRTI	7	13	7	10	4	6	5	6
Other PI + 2NRTI	9	16	10	14	3	4	4	5
Other regimens ²	14	25	10	14	6	8	16	18

1. January 1, 2008 – March 31, 2009

2. Includes mono/dual therapy and other HAART regimens

Table 3: Raltegravir combinations¹

Combination	(N=145)	%
+etravirine+ darunavir	17	12
+darunavir, no etravirine	34	23
+etravirine, no darunavir	15	10
+other boosted PIs ²	26	18
+other combination	53	36

1. Combinations include 2 or more antiretroviral drugs,
Based on last raltegravir regimen of all patients on raltegravir.
2. Includes raltegravir combinations with : kaletra, atazanavir and ritonavir,
fosamprenavir and ritonavir as well as tipranavir and ritonavir.

Table 4: Etravirine combinations¹

Combination	(N=46)	%
+raltegravir + darunavir	17	37
+darunavir, no raltegravir	9	20
+raltegravir, no darunavir	15	33
+other combination	5	11

1. Combinations include 2 or more antiretroviral drugs,
Based on last etravirine regimen of all patients on etravirine.